Topical application of integrin antagonists inhibits proliferative retinopathy

B. Riecke, E. Chavakis, R. G. Bretzel, T. Linn, K. T. Preissner, M. Brownlee, H. P. Hammes

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The expression of αv-integrins is highly selective for anglogenic endothelial cells; ligation inhibition by cyclic RGD peptides prevents pathological neovascularization in tumor or retinopathy models to a large extent. We have previously demonstrated that proliferative retinopathy in a mouse model of retinopathy of prematurity (ROP model) can be reduced by more than 70%. To minimize systemic side effects and unwanted interference with responsive angiogenesis, we investigated topical application of cyclic RGD-peptides. In preliminary experiments, we could exclude any inhibiting effects of the carrier solution containing EDTA, Na2S, mannitol, hydroxyethyl starch, and benzalconium chloride on the inhibitory effect of cyclic RGD peptides. Retinal presence of small molecular-mass integrin antagonists after topical application was confirmed using fluorescein-labeled cyclic RGD peptide. Topical application of the peptide to the eye inhibited proliferative retinopathy in a dose-dependent fashion with a maximum of almost 50%. These results suggest that small molecular-mass peptide antagonists of αv-type integrins are efficient in inhibiting proliferative retinopathy by topical application.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalHormone and Metabolic Research
Volume33
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Cyclic Peptides
Integrins
Molecular mass
Pathologic Neovascularization
Retinopathy of Prematurity
Peptides
Endothelial cells
Mannitol
Fluorescein
Edetic Acid
Starch
Ligation
Chlorides
Tumors
Endothelial Cells
arginyl-glycyl-aspartic acid
cyclic arginine-glycine-aspartic acid peptide
Neoplasms
Experiments

Keywords

  • α-type integrins
  • Angiogenesis
  • Diabetic retinopathy
  • RGD peptides

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Riecke, B., Chavakis, E., Bretzel, R. G., Linn, T., Preissner, K. T., Brownlee, M., & Hammes, H. P. (2001). Topical application of integrin antagonists inhibits proliferative retinopathy. Hormone and Metabolic Research, 33(5), 307-311. https://doi.org/10.1055/s-2001-15279

Topical application of integrin antagonists inhibits proliferative retinopathy. / Riecke, B.; Chavakis, E.; Bretzel, R. G.; Linn, T.; Preissner, K. T.; Brownlee, M.; Hammes, H. P.

In: Hormone and Metabolic Research, Vol. 33, No. 5, 2001, p. 307-311.

Research output: Contribution to journalArticle

Riecke, B, Chavakis, E, Bretzel, RG, Linn, T, Preissner, KT, Brownlee, M & Hammes, HP 2001, 'Topical application of integrin antagonists inhibits proliferative retinopathy', Hormone and Metabolic Research, vol. 33, no. 5, pp. 307-311. https://doi.org/10.1055/s-2001-15279
Riecke B, Chavakis E, Bretzel RG, Linn T, Preissner KT, Brownlee M et al. Topical application of integrin antagonists inhibits proliferative retinopathy. Hormone and Metabolic Research. 2001;33(5):307-311. https://doi.org/10.1055/s-2001-15279
Riecke, B. ; Chavakis, E. ; Bretzel, R. G. ; Linn, T. ; Preissner, K. T. ; Brownlee, M. ; Hammes, H. P. / Topical application of integrin antagonists inhibits proliferative retinopathy. In: Hormone and Metabolic Research. 2001 ; Vol. 33, No. 5. pp. 307-311.
@article{3bb610b901e9448eadcbab358cbb61db,
title = "Topical application of integrin antagonists inhibits proliferative retinopathy",
abstract = "The expression of αv-integrins is highly selective for anglogenic endothelial cells; ligation inhibition by cyclic RGD peptides prevents pathological neovascularization in tumor or retinopathy models to a large extent. We have previously demonstrated that proliferative retinopathy in a mouse model of retinopathy of prematurity (ROP model) can be reduced by more than 70{\%}. To minimize systemic side effects and unwanted interference with responsive angiogenesis, we investigated topical application of cyclic RGD-peptides. In preliminary experiments, we could exclude any inhibiting effects of the carrier solution containing EDTA, Na2S, mannitol, hydroxyethyl starch, and benzalconium chloride on the inhibitory effect of cyclic RGD peptides. Retinal presence of small molecular-mass integrin antagonists after topical application was confirmed using fluorescein-labeled cyclic RGD peptide. Topical application of the peptide to the eye inhibited proliferative retinopathy in a dose-dependent fashion with a maximum of almost 50{\%}. These results suggest that small molecular-mass peptide antagonists of αv-type integrins are efficient in inhibiting proliferative retinopathy by topical application.",
keywords = "α-type integrins, Angiogenesis, Diabetic retinopathy, RGD peptides",
author = "B. Riecke and E. Chavakis and Bretzel, {R. G.} and T. Linn and Preissner, {K. T.} and M. Brownlee and Hammes, {H. P.}",
year = "2001",
doi = "10.1055/s-2001-15279",
language = "English (US)",
volume = "33",
pages = "307--311",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - Topical application of integrin antagonists inhibits proliferative retinopathy

AU - Riecke, B.

AU - Chavakis, E.

AU - Bretzel, R. G.

AU - Linn, T.

AU - Preissner, K. T.

AU - Brownlee, M.

AU - Hammes, H. P.

PY - 2001

Y1 - 2001

N2 - The expression of αv-integrins is highly selective for anglogenic endothelial cells; ligation inhibition by cyclic RGD peptides prevents pathological neovascularization in tumor or retinopathy models to a large extent. We have previously demonstrated that proliferative retinopathy in a mouse model of retinopathy of prematurity (ROP model) can be reduced by more than 70%. To minimize systemic side effects and unwanted interference with responsive angiogenesis, we investigated topical application of cyclic RGD-peptides. In preliminary experiments, we could exclude any inhibiting effects of the carrier solution containing EDTA, Na2S, mannitol, hydroxyethyl starch, and benzalconium chloride on the inhibitory effect of cyclic RGD peptides. Retinal presence of small molecular-mass integrin antagonists after topical application was confirmed using fluorescein-labeled cyclic RGD peptide. Topical application of the peptide to the eye inhibited proliferative retinopathy in a dose-dependent fashion with a maximum of almost 50%. These results suggest that small molecular-mass peptide antagonists of αv-type integrins are efficient in inhibiting proliferative retinopathy by topical application.

AB - The expression of αv-integrins is highly selective for anglogenic endothelial cells; ligation inhibition by cyclic RGD peptides prevents pathological neovascularization in tumor or retinopathy models to a large extent. We have previously demonstrated that proliferative retinopathy in a mouse model of retinopathy of prematurity (ROP model) can be reduced by more than 70%. To minimize systemic side effects and unwanted interference with responsive angiogenesis, we investigated topical application of cyclic RGD-peptides. In preliminary experiments, we could exclude any inhibiting effects of the carrier solution containing EDTA, Na2S, mannitol, hydroxyethyl starch, and benzalconium chloride on the inhibitory effect of cyclic RGD peptides. Retinal presence of small molecular-mass integrin antagonists after topical application was confirmed using fluorescein-labeled cyclic RGD peptide. Topical application of the peptide to the eye inhibited proliferative retinopathy in a dose-dependent fashion with a maximum of almost 50%. These results suggest that small molecular-mass peptide antagonists of αv-type integrins are efficient in inhibiting proliferative retinopathy by topical application.

KW - α-type integrins

KW - Angiogenesis

KW - Diabetic retinopathy

KW - RGD peptides

UR - http://www.scopus.com/inward/record.url?scp=0034956835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034956835&partnerID=8YFLogxK

U2 - 10.1055/s-2001-15279

DO - 10.1055/s-2001-15279

M3 - Article

VL - 33

SP - 307

EP - 311

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 5

ER -